Mesoblast names Bill Burns as vice chairman
Mr. Burns brings to Mesoblast extensive international commercial, business development, and operational experience in the pharmaceutical industry.
From 1991-1998, he was Global Head of Strategic Marketing and Business Development at F. Hoffmann-La Roche Ltd. From 2000-2009, Mr. Burns was a Member of the Corporate Executive Committee of the Roche Group and from 2001-2009, he was CEO of Roche Pharmaceuticals.
During this time, Mr. Burns had significant involvement in the privatisation of Genentech, the integration of Boehringer Mannheim and the negotiations that resulted in Roche becoming a majority owner of Chugai Pharmaceuticals in Japan.
Mr. Burns has been a non-executive Director of Chugai Pharmaceuticals (2001-2014), Genentech (2004-2014), Roche (2010-2014), and Shire Pharmaceuticals plc since 2010, most recently as Senior Independent Non-Executive Director.
His other key appointments in healthcare include roles as Vice Chairman, Vestergaard, Governor and Trustee for Wellcome Trust, Trustee for the Institute of Cancer Research, London, and Scientific Advisory Board Member for the University of Cologne/Bonn Center for Integrated Oncology. ■
LATEST MOVES FROM New York
- CBS Corporation extends agreement with CEO Leslie Moonves
- iFresh appoints Alfred Chung-Chieh Ying as CFO
- Ralph Lauren Corporation names Patrice Louvet president and CEO
- AIG appoints Brian Duperreault as CEO
- Hardinge appoints Charles P. Dougherty as CEO
More inside POST
Chevron Q1 net income $2.68 billion Earnings